Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

A bloodstream infection with Streptococcus gallolyticus, particularly subspecies gallolyticus (historically S. bovis biotype I), can be a clue to an unsuspected colon polyp or cancer. The bacterium can also infect heart valves. Its detection calls for treatment of the infection and evaluation of both the heart and colon. It does not mean that every infected person has cancer, and treating the infection does not replace the colon evaluation.

Clinical Definition

S. gallolyticus subsp. gallolyticus bacteremia or endocarditis has a strong association with colorectal adenomas and adenocarcinoma. This organism belongs to the S. bovis/equinus complex, whose members differ in their associations with neoplasia. It is a nonenterococcal group D, gram-positive streptococcus that can colonize the gut. Bloodstream invasion may occur across abnormal mucosa. A positive blood culture prompts colorectal and endocarditis evaluation; it neither proves cancer nor establishes that the organism caused the tumor.

Inciting Event

  • Gut carriage can precede invasive infection, but colonization alone is not proof of cancer or a demonstrated initiating event for every tumor.

  • Colorectal neoplasia may favor bacterial colonization and translocation; the direction and mechanisms of the association are not fully resolved in humans.

  • Disrupted intestinal mucosa can allow bacteria into blood; bacteremia may then seed susceptible cardiac valves.

  • General colorectal-cancer risk factors do not identify a specific exposure that causes S. gallolyticus-associated disease.

Latency Period

  • There is no established human interval from S. gallolyticus colonization to colorectal cancer. A lesion may already be present when bacteremia is detected.

  • Adenoma-carcinoma progression generally occurs over years, but this does not define the timing of the bacterial association.

  • A negative initial colon evaluation does not define lifetime risk; subsequent surveillance depends on examination quality, findings, symptoms and specialist assessment.

Diagnostic Delay

  • Nonspecific early symptoms such as fatigue or mild abdominal discomfort delay clinical suspicion.

  • Waiting for routine screening eligibility after bacteremia can delay diagnosis; the organism provides a separate reason for colon evaluation.

  • Attribution of symptoms to benign gastrointestinal conditions such as hemorrhoids or irritable bowel syndrome.

  • Failure to perform colonoscopy after S. gallolyticus bacteremia delays detection of underlying neoplasia.

Clinical Presentation


Signs & Symptoms

  • Fever, chills or persistent bacteremia may be the initial presentation, even without gastrointestinal symptoms.

  • Change in bowel habits including diarrhea, constipation, or narrowing of stool caliber.

  • Rectal bleeding or occult blood loss with iron-deficiency anemia can signal a lesion, but their absence does not exclude one.

  • Abdominal pain or cramping may occur with tumor growth or obstruction.

  • Unintentional weight loss and fatigue reflect systemic effects of malignancy.

History of Present Illness

  • Ask about fever, rigors, duration of constitutional symptoms and prior antibiotic exposure, as well as bowel changes.

  • Occult or overt gastrointestinal bleeding presenting as melena or hematochezia.

  • Unexplained iron deficiency anemia due to chronic blood loss from tumor.

  • Dyspnea, focal neurologic symptoms or new limb/abdominal pain can indicate complications of endocarditis and require prompt assessment.

  • Weight loss and fatigue in advanced disease stages.

Past Medical History

  • Prior S. gallolyticus bloodstream infection should prompt review of previous endocarditis assessment and the completeness and findings of colon evaluation.

  • Long-standing ulcerative colitis or Crohn colitis increases colorectal-neoplasia risk according to disease extent and duration.

  • Previous colorectal adenomas or polyps indicate predisposition to malignancy.

  • Record valve disease, prosthetic valves, prior endocarditis and hepatobiliary disease when evaluating possible sources and complications of bacteremia.

Family History

  • First-degree relatives with colorectal cancer increase individual risk significantly.

  • Inherited syndromes such as Lynch syndrome (hereditary nonpolyposis colorectal cancer) are associated with early-onset colorectal cancer.

  • Familial adenomatous polyposis caused by APC gene mutations leads to multiple colorectal adenomas and cancer.

  • Family history of colorectal cancer or polyposis informs inherited risk; a family history of S. gallolyticus infection is not an established hereditary cancer marker.

Physical Exam Findings

  • An abdominal or rectal mass may be detectable, but a normal examination does not exclude colorectal neoplasia.

  • Pallor and tachycardia can be observed due to chronic blood loss anemia.

  • Hepatomegaly may be present if there is metastatic liver involvement.

  • A new murmur, signs of heart failure or peripheral embolic findings raise concern for endocarditis; their absence does not exclude it.

  • Signs of cachexia such as weight loss and muscle wasting are common in late-stage disease.

Diagnostic Workup


Diagnostic Criteria

Blood cultures identify S. gallolyticus infection. Assess for endocarditis using clinical findings, repeated cultures and cardiac imaging; bacteremia alone does not establish valve infection. Evaluate the colon for neoplasia, with histology determining adenoma versus carcinoma. These are related but separate diagnoses, and some patients have no colorectal lesion identified.

Pathophysiology


Key Mechanisms

  • The central clinical link is bacteremia/endocarditis with occult colorectal neoplasia, strongest for subspecies gallolyticus; not every S. bovis-group isolate has identical implications.

  • Abnormal mucosa may facilitate translocation, and bacterial adhesion can support tissue colonization. These mechanisms do not establish an obligatory cancer-causing sequence.

  • Experimental studies show beta-catenin-dependent proliferation in selected cancer cell lines and increased tumor burden in mouse models; their results should not be equated with proven causation in every human case.

  • Do not infer a clinically established toxin-induced DNA-damage pathway or a fixed cancer latency from experimental observations.

  • Classic laboratory clues are bile-esculin positivity, PYR negativity and lack of growth in 6.5% NaCl, distinguishing the traditional S. bovis pattern from enterococci. Modern identification should resolve species/subspecies where possible.

InvolvementDetails
Organs

Colon is the main organ affected by colorectal cancer, where tumors commonly arise from adenomatous polyps

The rectum can harbor a neoplasm; treatment depends on stage and anatomy rather than the blood-culture result alone.

Liver is the most common site of distant metastasis in colorectal cancer, impacting prognosis and management

Tissues

Colonic mucosa is the primary site of malignant transformation in colorectal cancer

Submucosa and muscularis propria are invaded as colorectal cancer progresses, indicating deeper tumor penetration

Cardiac valve endocardium may become infected with vegetations; neoplasms can separately spread to regional lymph nodes.

Cells

Colorectal adenocarcinoma cells are malignant epithelial cells driving tumor growth and metastasis

Tumor-associated macrophages promote tumor progression and immunosuppression in the colorectal cancer microenvironment

T lymphocytes mediate anti-tumor immune responses but may be suppressed in the tumor microenvironment

Chemical Mediators

Vascular endothelial growth factor (VEGF) promotes angiogenesis essential for tumor growth and metastasis

Epidermal growth factor receptor (EGFR) signaling drives colorectal cancer cell proliferation and survival

CEA may help monitor established colorectal cancer but cannot confirm, exclude or screen for it.

Treatments


Pharmacological Treatments

  • Fluoropyrimidines (e.g., 5-fluorouracil)

    • Mechanism:
      • Inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing colorectal cancer cells

    • Side effects:
      • Myelosuppression

      • Mucositis

      • Diarrhea

      • Hand-foot syndrome

    • Clinical role:
      • For confirmed cancer when stage and biomarkers warrant fluoropyrimidine-based treatment; does not treat S. gallolyticus infection.

  • Oxaliplatin

    • Mechanism:
      • Forms DNA crosslinks leading to apoptosis of colorectal cancer cells

    • Side effects:
      • Cold-triggered acute sensory symptoms and cumulative peripheral neuropathy

      • Myelosuppression

      • Nausea

    • Clinical role:
      • Part of selected adjuvant or metastatic colorectal-cancer regimens, such as FOLFOX; not treatment of bacteremia.

  • Irinotecan

    • Mechanism:
      • The active metabolite SN-38 inhibits topoisomerase I; reduced UGT1A1-mediated glucuronidation can increase toxicity.

    • Side effects:
      • Early cholinergic diarrhea or severe delayed diarrhea

      • Myelosuppression

      • Alopecia

    • Clinical role:
      • Part of metastatic colorectal-cancer regimens such as FOLFIRI; not standard routine adjuvant therapy after resection.

  • Bevacizumab

    • Mechanism:
      • Monoclonal antibody against VEGF, inhibiting tumor angiogenesis

    • Side effects:
      • Hypertension and proteinuria

      • Bleeding

      • Thromboembolism

      • Impaired wound healing and gastrointestinal perforation

    • Clinical role:
      • Antiangiogenic adjunct in selected metastatic colorectal-cancer regimens; not routine adjuvant treatment or antimicrobial therapy.

  • Cetuximab

    • Mechanism:
      • Monoclonal antibody targeting EGFR, blocking growth signals in colorectal cancer cells

    • Side effects:
      • Acneiform rash

      • Hypomagnesemia

      • Infusion reactions

    • Clinical role:
      • Selected metastatic treatment based on molecular profile and tumor sidedness; conventional use generally requires expanded RAS wild-type status, with specific KRAS G12C combination exceptions.

  • Ceftriaxone

    • Mechanism:
      • A beta-lactam that binds penicillin-binding proteins and inhibits bacterial cell-wall cross-linking.

    • Side effects:
      • Hypersensitivity reactions

      • Antibiotic-associated diarrhea, including C. difficile colitis

      • Biliary sludge or pseudolithiasis

    • Clinical role:
      • A treatment option for susceptible S. gallolyticus infection; penicillin G is another. Endocarditis commonly needs 4 weeks for native valves or 6 for prosthetic valves. Regimen and duration depend on susceptibility, complications and specialist assessment.

Non-pharmacological Treatments

  • Resect or otherwise treat a confirmed colorectal lesion according to its histology, stage and patient factors; bacteremia by itself is not an indication for cancer surgery.

  • Diagnostic colonoscopy may permit polypectomy; removing a polyp does not replace antimicrobial treatment for bloodstream or valve infection.

  • Use radiation only for selected cancer indications, especially rectal cancer. Endocarditis may separately require valve surgery for complications.

  • Nutritional support and symptom management to improve quality of life in advanced disease

Prevention


Pharmacological Prevention

  • Aspirin is not routinely started solely for colorectal-cancer prevention in average-risk adults because benefit is uncertain and bleeding can occur; hereditary-syndrome decisions are individualized.

  • COX-2 inhibitors and other NSAIDs are not routine population chemoprevention because of gastrointestinal, cardiovascular and renal harms.

  • Vitamin D supplements have no established role in preventing S. gallolyticus-associated colorectal cancer.

  • Statins should be prescribed for appropriate lipid/cardiovascular indications, not as established colorectal-cancer chemoprevention.

  • Antibiotics treat active bacteremia or endocarditis; they have not been established as colorectal-cancer prevention and do not remove the need to evaluate the colon.

Non-pharmacological Prevention

  • Routine average-risk colorectal screening generally covers ages 45-75, with individualized decisions at 76-85. S. gallolyticus bacteremia requires diagnostic evaluation, rather than waiting for routine screening eligibility.

  • Dietary modifications including increased fiber intake and reduced red/processed meat consumption.

  • Smoking cessation and limiting alcohol intake reduce colorectal cancer risk.

  • Regular physical activity and healthy weight support general colorectal-cancer risk reduction; no specific protective effect against this bacterial association is established.

  • Prompt evaluation of S. gallolyticus bacteremia to detect underlying colorectal neoplasia early.

Outcome & Complications


Complications

  • Bowel obstruction due to tumor growth causing luminal narrowing.

  • Perforation of the colon leading to peritonitis.

  • Metastatic spread to liver, lungs, and lymph nodes.

  • Cancer may cause thrombosis and chronic blood-loss anemia; endocarditis can cause emboli and valve dysfunction. Anemia is not automatically a paraneoplastic syndrome.

  • Infective endocarditis caused by S. gallolyticus bacteremia.

Short-term Sequelae Long-term Sequelae
  • Acute gastrointestinal bleeding causing anemia and hemodynamic instability.

  • Bowel obstruction symptoms including severe abdominal pain and vomiting.

  • Sepsis from bacterial translocation or infective endocarditis.

  • Electrolyte imbalances secondary to obstruction or malnutrition.

  • Postoperative complications following tumor resection.

  • Chronic anemia from ongoing occult bleeding.

  • Metastatic disease progression leading to organ failure.

  • Recurrence of colorectal cancer after treatment.

  • Persistent valve dysfunction may follow endocarditis; bowel dysfunction or a stoma may follow cancer surgery, depending on the operation.

  • Psychosocial impact and decreased quality of life due to chronic illness.

Differential Diagnoses


Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis) versus Inflammatory Bowel Disease (IBD)

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis)

Inflammatory Bowel Disease (IBD)

Colorectal neoplasia may be clinically silent when bacteremia or endocarditis prompts evaluation; symptoms do not reliably indicate stage.

Chronic relapsing-remitting course with abdominal pain and diarrhea

Adenocarcinoma arising from dysplastic epithelium with glandular formation

Chronic intestinal inflammation: granulomas may occur in Crohn disease but are not required; ulcerative colitis typically has chronic mucosal and crypt architectural changes.

Iron-deficiency anemia may suggest bleeding; CEA is neither sensitive nor specific enough to establish cancer.

Inflammatory markers may rise, but pANCA/ASCA neither establish nor exclude IBD; endoscopy, histology and clinical context are needed.

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis) versus Diverticulitis

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis)

Diverticulitis

CT may suggest a mass but cannot replace tissue diagnosis; inflammation can overlap.

Diverticula, wall thickening and fat stranding favor diverticulitis; appropriate follow-up may still be needed to exclude malignancy.

Insidious onset with occult bleeding or anemia

Acute onset of left lower quadrant pain with fever and leukocytosis

Treat bloodstream infection and any confirmed neoplasm separately; cancer therapy depends on the lesion.

Mild uncomplicated diverticulitis may improve with supportive care; antibiotics are selective, and improvement does not itself exclude a tumor.

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis) versus Colorectal Polyps (Adenomatous)

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis)

Colorectal Polyps (Adenomatous)

Invasive carcinoma extends into submucosa or deeper.

An adenoma has dysplastic epithelium without submucosal invasion; adenomas are themselves part of the bacterial association.

Adequate tissue sampling establishes invasion; superficial samples may miss it.

Complete polyp assessment defines dysplasia and evaluates for an invasive component.

May present with symptoms related to tumor mass or metastasis

Often asymptomatic and detected on screening colonoscopy

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis) versus Infective Endocarditis with S. gallolyticus Bacteremia without Colorectal Cancer

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis)

Infective Endocarditis with S. gallolyticus Bacteremia without Colorectal Cancer

The same organism may occur with adenoma, carcinoma or no detected neoplasia.

Endocarditis can occur without a detected colorectal lesion, but the culture still prompts colon evaluation.

Colonoscopy and histology establish colorectal neoplasia; assess separately for endocarditis.

Endocarditis is assessed with cultures, imaging and clinical criteria; a negative initial colonoscopy does not prove lifelong absence of neoplasia.

Both infection and any neoplasm need appropriate treatment.

Treat endocarditis with targeted antibiotics and assess surgical indications; clinical improvement does not replace colon evaluation.

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis) versus Hemorrhoidal Bleeding

Colorectal Cancer Association (Streptococcus gallolyticus - S. bovis)

Hemorrhoidal Bleeding

Bleeding or anemia may occur with or without coexisting hemorrhoids.

Internal hemorrhoids often cause painless bright-red bleeding or prolapse; thrombosed external hemorrhoids can be painful.

Risk increases with age but younger adults can have colorectal cancer.

Hemorrhoids occur across adult ages; age does not reliably exclude cancer.

Colonoscopy with appropriate tissue assessment identifies neoplasia.

Inspection and anoscopy can identify hemorrhoids but do not exclude a more proximal lesion; bacteremia still warrants the indicated workup.